TOR (target of rapamycin) and its mammalian ortholog mTOR have been discovered in an
effort to understand the mechanisms of action of the immunosuppressant drug rapamycin …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Autophagy is a major protein degradation pathway capable of upholding cellular
metabolism under nutrient limiting conditions, making it a valuable resource to highly …

The mammalian target of rapamycin (mTOR) is an ubiquitously expressed serine-threonine
kinase, which senses and integrates several intracellular and environmental cues to …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Glioblastoma is the most common and malignant brain cancer in adults. Current therapy
consisting of surgery followed by radiation and temozolomide has a moderate success rate …

Glioblastoma multiforme is the most malignant and aggressive type of brain tumor, with a
mean life expectancy of less than 15 months. This is due in part to the high resistance to …

Glioblastoma (GBM) is the most serious brain tumor and shows a high rate of drug
resistance. Wnt signaling is a very important pathway in GBM that can activate/inhibit other …

The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase
activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by …